These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19359162)

  • 1. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
    Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
    Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma Progression in vitro and in vivo.
    Ding L; Ren C; Yang L; Wu Z; Li F; Jiang D; Zhu Y; Lu J
    Drug Des Devel Ther; 2021; 15():1797-1810. PubMed ID: 33958857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
    Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
    J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
    Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
    Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
    Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
    Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
    To K; Zhao Y; Jiang H; Hu K; Wang M; Wu J; Lee C; Yokom DW; Stratford AL; Klinge U; Mertens PR; Chen CS; Bally M; Yapp D; Dunn SE
    Mol Pharmacol; 2007 Sep; 72(3):641-52. PubMed ID: 17595327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
    Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
    Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
    Zhu J; Huang JW; Tseng PH; Yang YT; Fowble J; Shiau CW; Shaw YJ; Kulp SK; Chen CS
    Cancer Res; 2004 Jun; 64(12):4309-18. PubMed ID: 15205346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
    Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
    Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
    Li J; Zhu J; Melvin WS; Bekaii-Saab TS; Chen CS; Muscarella P
    J Gastrointest Surg; 2006 Feb; 10(2):207-14. PubMed ID: 16455452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
    Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
    Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.
    Gao M; Yeh PY; Lu YS; Hsu CH; Chen KF; Lee WC; Feng WC; Chen CS; Kuo ML; Cheng AL
    Cancer Res; 2008 Nov; 68(22):9348-57. PubMed ID: 19010909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.
    Kersigo J; Gu L; Xu L; Pan N; Vijayakuma S; Jones T; Shibata SB; Fritzsch B; Hansen MR
    Laryngoscope; 2021 Jan; 131(1):E259-E270. PubMed ID: 32438526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of vestibular schwannoma cells with ErbB inhibitors.
    Bush ML; Burns SS; Oblinger J; Davletova S; Chang LS; Welling DB; Jacob A
    Otol Neurotol; 2012 Feb; 33(2):244-57. PubMed ID: 22222570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
    Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
    Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
    Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS
    Clin Cancer Res; 2007 Aug; 13(16):4750-8. PubMed ID: 17699852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.